CRISPR and the Commercialization of Gene-Based Therapies

Learning from the recent past to change the near future

The gene editing possibilities suggested by CRISPR/ Cas9 hold promise for treating a wide range of diseases, yet history offers innumerable reminders that novel therapies can be met with significant barriers to access, including high prices and reimbursement hurdles imposed by payers. Read our white paper – the final in a series.

Your form has been successfully submitted! Click the button below to access.
Read more


Read the rest of the papers in this CRISPR series:

CRISPR, Gene-Based Therapeutics, and Clinical Trials


Clinical Development of CRISPR-Based Therapies in Oncology